Beyond amyloid and dopamine: emerging technologies reshaping neurology

▤ Summary

This article reviews four emerging technologies that could reshape neurology, including larger gene-delivery systems, BBB-targeting therapies, brain-penetrant lysosomal drugs, and circuit-modulating compounds. It explains how current neurological drug development has been constrained by delivery limits, poor brain penetration, and incomplete understanding of disease biology. The piece highlights examples from Institute of Science Tokyo, Lys Therapeutics, Roche, Boston Children’s Hospital, Gain Therapeutics, Sanofi, and Penn State. It frames these technologies as early-stage approaches that may create new treatment options for neurodegenerative and rare brain diseases.

▦ Linked Companies